Fatigue after initiating rivaroxaban for venous thromboembolism

BACKGROUND: Rivaroxaban was the first new oral anticoagulant approved for treatment of venous thromboembolism (VTE). Clinical trials have shown that rivaroxaban is noninferior to conventional anticoagulation for VTE in efficacy and safety. Increased fatigue after the initiation of rivaroxaban has be...

全面介紹

Na minha lista:
書目詳細資料
發表在:Res Pract Thromb Haemost
Main Authors: Karlsvik, Tina Margrethe, Borgenvik, Thore Langfeldt, Aadalen, Mirjam, Utne, Kristin, Førsund, Eli, Jørgensen, Camilla Tøvik, Holst, René, Jelsness‐Jørgensen, Lars‐Petter, Ghanima, Waleed
格式: Artigo
語言:Inglês
出版: John Wiley and Sons Inc. 2020
主題:
Original Article: Thrombosis
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7292653/
https://ncbi.nlm.nih.gov/pubmed/32548556
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/rth2.12312
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍